NDC 36987-1119

Silk

Silk

Silk is a Intradermal; Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Nelco Laboratories, Inc.. The primary component is Bombyx Mori Fiber.

Product ID36987-1119_9cd5b8c5-a866-4089-90e5-a0ad15736698
NDC36987-1119
Product TypeHuman Prescription Drug
Proprietary NameSilk
Generic NameSilk
Dosage FormInjection, Solution
Route of AdministrationINTRADERMAL; SUBCUTANEOUS
Marketing Start Date1972-08-29
Marketing CategoryBLA / BLA
Application NumberBLA102192
Labeler NameNelco Laboratories, Inc.
Substance NameBOMBYX MORI FIBER
Active Ingredient Strength0 g/mL
Pharm ClassesNon-Standardized Insect Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Insect Proteins [CS],Silk [CS],Allergens [CS]
NDC Exclude FlagE
Listing Certified Through2017-12-31

Packaging

NDC 36987-1119-1

5 mL in 1 VIAL, MULTI-DOSE (36987-1119-1)
Marketing Start Date1972-08-29
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 36987-1119-2 [36987111902]

Silk INJECTION, SOLUTION
Marketing CategoryBLA
Application NumberBLA102192
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date1972-08-29
Inactivation Date2019-10-21

NDC 36987-1119-4 [36987111904]

Silk INJECTION, SOLUTION
Marketing CategoryBLA
Application NumberBLA102192
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date1972-08-29
Inactivation Date2019-10-21

NDC 36987-1119-3 [36987111903]

Silk INJECTION, SOLUTION
Marketing CategoryBLA
Application NumberBLA102192
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date1972-08-29
Inactivation Date2019-10-21

NDC 36987-1119-1 [36987111901]

Silk INJECTION, SOLUTION
Marketing CategoryBLA
Application NumberBLA102192
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date1972-08-29
Inactivation Date2019-10-21

Drug Details

Active Ingredients

IngredientStrength
BOMBYX MORI FIBER.1 g/mL

OpenFDA Data

SPL SET ID:1e43cb5e-cccc-4319-94a5-6c41bd9a3bc5
Manufacturer
UNII
RxNorm Concept Unique ID - RxCUI
  • 895075
  • 895204
  • 895065
  • 889660
  • 852696
  • 895061
  • 894749
  • 895304
  • 894917
  • 852482
  • 1006505
  • 894948
  • 852259
  • 895284
  • 895300
  • Pharmacological Class

    • Non-Standardized Insect Allergenic Extract [EPC]
    • Increased Histamine Release [PE]
    • Cell-mediated Immunity [PE]
    • Increased IgG Production [PE]
    • Insect Proteins [CS]
    • Silk [CS]
    • Allergens [CS]

    NDC Crossover Matching brand name "Silk" or generic name "Silk"

    NDCBrand NameGeneric Name
    36987-1117SilkSilk
    36987-1118SilkSilk
    36987-1119SilkSilk
    36987-1120SilkSilk
    54575-278SILKbombyx mori fiber

    Trademark Results [Silk]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    SILK
    SILK
    98831353 not registered Live/Pending
    Cameron, Timothy A
    2024-10-31
    SILK
    SILK
    98831353 not registered Live/Pending
    Glenn, Gary W
    2024-10-31
    SILK
    SILK
    98831353 not registered Live/Pending
    Gates, Jimmy E
    2024-10-31
    SILK
    SILK
    98831353 not registered Live/Pending
    Jenkins, Gary E
    2024-10-31
    SILK
    SILK
    98831353 not registered Live/Pending
    Rasboro, Johnathan L
    2024-10-31
    SILK
    SILK
    98771563 not registered Live/Pending
    Blockchain Game Partners, Inc.
    2024-09-26
    SILK
    SILK
    98771555 not registered Live/Pending
    Blockchain Game Partners, Inc.
    2024-09-26
    SILK
    SILK
    98737476 not registered Live/Pending
    LONZA WALKERSVILLE, INC.
    2024-09-06
    SILK
    SILK
    98204801 not registered Live/Pending
    Silknode
    2023-09-29
    SILK
    SILK
    98155163 not registered Live/Pending
    KOKUYO KABUSHIKI KAISHA
    2023-08-29
    SILK
    SILK
    98041170 not registered Live/Pending
    Holonym Foundation
    2023-06-13
    SILK
    SILK
    97797683 not registered Live/Pending
    Johnson & Johnson
    2023-02-16

    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.